Critical Comparison: Ocera Therapeutics (TZYM) and Its Peers
Ocera Therapeutics (NASDAQ: TZYM) is one of 50 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Ocera Therapeutics to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, profitability, institutional ownership and risk.
Earnings & Valuation
This table compares Ocera Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Ocera Therapeutics Competitors||$585.03 million||$106.82 million||56.92|
Ocera Therapeutics’ competitors have higher revenue and earnings than Ocera Therapeutics. Ocera Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Ocera Therapeutics has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Ocera Therapeutics’ competitors have a beta of 1.18, meaning that their average stock price is 18% more volatile than the S&P 500.
This is a summary of recent ratings for Ocera Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ocera Therapeutics Competitors||129||800||1742||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 12.77%. Given Ocera Therapeutics’ competitors higher probable upside, analysts plainly believe Ocera Therapeutics has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Ocera Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ocera Therapeutics Competitors||-13,462.32%||-176.39%||-24.75%|
Ocera Therapeutics competitors beat Ocera Therapeutics on 6 of the 8 factors compared.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Receive News & Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.